Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Minnesota: - Fairview Ridges Hospital — Burnsville, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Cambridge Medical Center — Cambridge, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Fairview Ridges Hospital — Burnsville, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Cambridge Medical Center — Cambridge, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Minnesota: - Children's Hospitals and Clinics of Minnesota - Minneapolis — Minneapolis, Minnesota
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Minnesota: - Masonic Cancer Center — Minneapolis, Minnesota
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) …
Sponsor: BeOne Medicines
NCT ID: NCT07277231
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Minnesota: - Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
- Essentia Health Hibbing Clinic — Hibbing, Minnesota
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Minnesota: - Children's Hospitals and Clinics of Minnesota - Minneapolis — Minneapolis, Minnesota
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Minnesota: - Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
- Essentia Health Hibbing Clinic — Hibbing, Minnesota
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younge…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06672146
Sites in Minnesota: - Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
- Essentia Health Hibbing Clinic — Hibbing, Minnesota
Phase 1, Phase 2 Recruiting Industry
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Sponsor: Vironexis Biotherapeutics Inc.
NCT ID: NCT06533579
Sites in Minnesota: - Mayo Clinic, Clinical Trials Referral Office — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Sponsor: AstraZeneca
NCT ID: NCT06542250
Sites in Minnesota: - Research Site — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 1 year will be eligible to participate…
Sponsor: Imviva Bio
NCT ID: NCT07070219
Sites in Minnesota: - Mayo Clinic - Rochester — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Richter transformation is a rare condition i…
Sponsor: Mayo Clinic
NCT ID: NCT05388006
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40m…
Sponsor: Masonic Cancer Center, University of Minnesota
NCT ID: NCT07493538
Sites in Minnesota: - Masonic Cancer Center at University of Minnesota — Minneapolis, Minnesota
Phase 2 Recruiting Academic/Other
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility…
Sponsor: Masonic Cancer Center, University of Minnesota
NCT ID: NCT05735717
Sites in Minnesota: - University of Minnesota Masonic Cancer Center — Minneapolis, Minnesota
Phase 1 Recruiting Network
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic…
Sponsor: Children's Oncology Group
NCT ID: NCT06247787
Sites in Minnesota: - University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
Phase 1 Recruiting Industry
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell N…
Sponsor: Imugene Limited
NCT ID: NCT03666000
Sites in Minnesota: - University of Minnesota — Minneapolis, Minnesota
Phase 1 Recruiting Industry
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exha…
Sponsor: Nerviano Medical Sciences
NCT ID: NCT06549790
Sites in Minnesota: - Mayo Clinic Cancer Center (MCCC) - Rochester — Rochester, Minnesota
Phase 1 Recruiting Industry
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic ly…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05091424
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 1 Recruiting Academic/Other
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with cemiplim…
Sponsor: Mayo Clinic
NCT ID: NCT06508463
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Essentia Health-St. Joseph's Medical Center — Brainerd, Minnesota
- Essentia Health - Duluth Clinic — Duluth, Minnesota
- St. Luke's Hospital of Duluth — Duluth, Minnesota
- Lake Region Healthcare — Fergus Falls, Minnesota